|Bid||1.03 x 1400|
|Ask||1.27 x 1200|
|Day's Range||1.0200 - 1.0800|
|52 Week Range||0.8300 - 5.5400|
|Beta (3Y Monthly)||1.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Lindsay Rosenwald became the CEO of Fortress Biotech, Inc. (NASDAQ:FBIO) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
NEW YORK, Nov. 19, 2018 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel.
National Holdings Corporation (NHLD) (“National” or the “Company”), a leading full-service independent brokerage, investment banking, trading, insurance, accounting and asset management firm, today announced that B. Riley Financial, Inc. (RILY) (“B. Riley”), through a wholly owned subsidiary, has entered into an agreement to acquire Fortress Biotech, Inc.’s (FBIO) (“Fortress”) majority stake in National. Under the terms of the agreement, B. Riley will purchase 7,037,482 shares of National from Fortress, a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.
Acquires 24 percent of National Holdings’ outstanding sharesUp to an additional 32 percent of shares to be purchased following FINRA approval LOS ANGELES, Nov. 19, 2018 -- B..
NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
MUMBAI, India & NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of the leading global pharmaceutical company Cipla Limited, today announced that it has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company focused on the development and commercialization of intravenous (IV) Tramadol. The transaction will be subject to Avenue stockholders’ and regulatory approvals, and other closing conditions.
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 37.29% and -1.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the New York-based company said it had a loss of 37 cents. The biopharmaceutical company posted revenue of $63.7 million in the period. The company's shares closed at $1.09. A year ...
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced the appointment of Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer (“CMO”). Dr. Sersch will oversee the clinical development of Mustang’s pipeline in CAR T technology and gene therapies. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are delighted to welcome Martina to the Mustang leadership team.
If you want to know who really controls Fortress Biotech Inc (NASDAQ:FBIO), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...
NEW YORK, Sept. 27, 2018-- Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present a company ...
NEW YORK, Sept. 27, 2018-- National Holdings Corporation, a leading full-service independent brokerage, investment banking, trading, insurance, accounting and asset management firm, today announced the ...
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...